¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"growth rate"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • energy metabolic rate
    ¿¡³ÊÁö´ë»çÀ²
  • erythrocyte sedimentation rate
    ÀûÇ÷±¸Ä§°­¼Óµµ, Ç÷ħ¼Óµµ
  • fatality rate
    Ä¡¸í·ü
  • fertility rate
    »ý½Ä·ü
  • fetal death rate
    žƻç¸Á·ü
  • fetal heart rate
    žƽɹڼö
  • filtration rate
    ¿©°úºñ, ¿©°úÀ², ¿©°ú¼Óµµ
  • five-year survival rate
    ¿À³â»ýÁ¸À²
  • fixed rate pacemaker
    °íÁ¤¼Óµµ¹Úµ¿Á¶À²±â
  • flow rate
    1. À¯¼Ó 2. À¯·®
  • fractional fibrinogen catabolic rate
    ºÐȹº°¼¶À¯¼Ò¿ø´ë»çÀ²
  • frame rate
    È­¸é¹ß»ý·ü, È­¸éÀ²
  • general fertility rate
    ÀϹݻý½Ä·ü
  • glomerular filtration rate
    »ç±¸Ã¼¿©°úÀ², Å丮¿©°úÀ²
  • gross reproduction rate
    ÃÑÀç»ý»êÀ²
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • disability rate
    Àå¾ÖÀ²
  • disappearance rate
    ¼Ò½Ç·ü
  • divorce rate
    ÀÌÈ¥À²
  • dose rate
    ¼±·®·ü
  • dose rate effect
    ¼±·®À²È¿°ú
  • dose rate meter
    ¼±·®À²°è, ¼±·®·üÃøÁ¤±â
  • dose rate variation
    ¼±·®·üº¯ÀÌ
  • early neonatal mortality rate
    ½Å»ý¾Æ»ç¸Á·ü
  • egg negative conversion rate
    Ãæ¶õÀ½ÀüÀ²
  • egg reduction rate
    Ãæ¶õ°¨¼ÒÀ²
  • energy fluence rate
    ¿¡³ÊÁöÇ÷ç¾ð½ºÀ², ¿¡³ÊÁö¿µÇâ·ü
  • energy metabolic rate
    ¿¡³ÊÁö´ë»çÀ²
  • erythrocyte sedimentation rate
    ÀûÇ÷±¸Ä§°­¼Óµµ, Ç÷ħ¼Óµµ
  • exposure rate
    ÇÇÆø·ü
  • rate limiting enzyme
    ¼ÓµµÁ¶ÀýÈ¿¼Ò
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • growth curvature
    ¼ºÀå°î¼±(¡­ÍØàÊ).
  • growth curve
    Áõ½Ä°î¼±, ¼ºÀå°î¼±.
  • growth curve
    Áõ½Ä°î¼±
  • growth curve, one-step
    ÀÏȸÁõ½Ä°î¼±
  • growth curve, single-step
    ÀÏȸÁõ½Ä°î¼±
  • growth cycle
    Áõ½ÄÁÖ±â
  • growth defect
    ¼ºÀå°áÇÔ
  • growth delay
    ¼ºÀåÁö¿¬
  • growth factor
    ¼ºÀå ÀÎÀÚ
  • growth factor
    ¼ºÀåÀÎÀÚ(à÷íþì×í­).
  • growth factor
    Áõ½ÄÀÎÀÚ
  • growth factor
    ¼ºÀå ÀÎÀÚ(à÷íþ ì×í­)
  • growth factor, B cell (BCGF)
    B¼¼Æ÷ Áõ½ÄÃËÁøÀÎÀÚ
  • growth failure
    ¼ºÀåºÎÀü(à÷íþÝÕîï).
  • growth form
    ¼ºÀåÇü(¡­úþ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • logarithmic growth
    ·Î±×Áõ½Ä(ÊÙÌ¡Ëà).
  • logarithmic growth phase
    ´ë¼öÁõ½Ä±â, Áö¼öÁõ½Ä±â
  • macroadenoma,growth hormone-secreting
    ¼ºÀåÈ£¸£¸ó ºÐºñ¼º(à÷íþ¡­ ÝÂÝôàõ)
  • macrophage,macrophage derived growth factor
    ´ë½Ä¼¼Æ÷±â¿ø ¼ºÀåÀÎÀÚ(¡­ÑÃê¹ à÷íþì×í­)
  • maximum stationary phase (of growth)
    (Áõ½Ä)±Ø´ëÁ¤Áö±â(ñòãÖпÓÞïÎò­Ñ¢).
  • membranous bone growth
    ¸·»ó°ñ ¼ºÀå(دßÒÍéà÷íþ).
  • membranous bone growth
    ¸·»ó°ñ¼ºÀå(¡­ßÒÍéà÷íþ)
  • new growth
    ½Å»ý¼º.(º´¸®)½Å»ý¹°(ãæßæÚª).
  • new growth
    ½Å»ý¼º(ãæßæàõ).½Å»ý¹°(ãæßæÚª)
  • occupational growth
    Á÷¾÷Àû ¼ºÀå (ÊÙËøËÛËö).
  • one step growth
    ÀÏ´ÜÁõ½Ä(ìéÓ«ñòãÖ).
  • one step growth curve
    ÀÏ´ÜÁõ½Ä°î¼±(¡­ÍØàÊ).
  • one step growth experiment
    ÀÏ´ÜÁõ½Ä½ÇÇè(¡­ãùúÐ).
  • organotypic growth
    ±â°üÇüÀû ¼ºÀå(ÐïίúþîÜà÷íþ)
  • pathologic growth
    º´Àû¼ºÀå(Ü»îÜà÷íþ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
PRR proton relaxation rate; pulse repetition rate
RRR regular rhythm and rate; renin release rate (or ratio)
SER sebum excretion rate; sensitizer enhancement ratio; sensory evoked response; service; smooth endopla...
SR sarcoplasmic reticulum; saturation recovery; scanning radiometer; screen; secretion rate; sedimentat...
TPR temperature, pulse, and respiration; testosterone production rate; third party reimbursement; total ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
FSR Fractional synthesis rate
FSR fractional synthetic rate
GER Gastric emptying rate
GFR Glomeoular Filtration Rate
GRF Glomerular filtration rate
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
accretionary growth Growth by an increase of intercellular material.
(05 Mar 2000)
appositional growth Growth accomplished by the addition of new layers on those previously formed; e.g., the addition of lamellae in the formation of bone; it is the characteristic method of growth when rigid materials are involved.
(05 Mar 2000)
auxetic growth Growth by increase in the size of component cells.
Synonym: intussusceptive growth.
(05 Mar 2000)
bacterial growth Growth of a bacterial culture either by increase in cell material or cell number.
(05 Mar 2000)
B-cell differentiation/growth factors Various substances, usually obtained from the supernatant of T-cell cultures, such as interleukin 4, 5, and 6. These substances are necessary for B-cell growth, maturation, and differentiation into plasma cells or B memory cells.
(05 Mar 2000)
biphasic growth curve <cell culture, microbiology> A particular type of growth curve seen in cultured microorganisms in which they have two exponential growth stages separated by a plateau phase. This double-hump curve is produced when the microbes are cultured using two carbon sources, one of which must be used up before the second can be used.
(19 Jan 1998)
bovine growth hormone <endocrinology> A hormone secreted by the bovine pituitary gland. It is used to increase milk production by improving the feed efficiency in dairy cattle.
(14 Nov 1997)
brain-derived growth factor <growth factor> Small basic protein purified from pig brain, a member of the family of neurotrophic factors that also includes Nerve Growth Factor and neurotrophin 3.
In contrast to nerve growth factor, brain-derived neurotrophic factor is predominanantly (though not exclusively) localised in the CNS. It supports the survival of primary sensory neurons originating from the neural crest and ectodermal placodes that are not responsive to NGF.
In the brain brain-derived neurotrophic factor has a trophic action on retinal, cholinergic, and dopaminergic neurons, and in the peripheral nervous system it acts on both motor and sensory neurons.
Acronym: BDGF
(12 Dec 1998)
capon-comb-growth test A test for androgenic activity, based upon the stimulation of comb growth in capons (castrated cockerels) or immature roosters.
Synonym: capon-comb-growth test, cock's comb test.
(05 Mar 2000)
radial growth phase The early pattern of growth of cutaneous malignant melanoma, in which tumour cells spread laterally in the epidermis.
(05 Mar 2000)
vascular endothelial growth factor A growth factor that is responsible for the growth of blood vessels.
(12 Dec 1998)
mammary derived growth inhibitor Fatty acid binding protein that inhibits proliferation of mammary carcinoma cells.
(18 Nov 1997)
receptors, epidermal growth factor-urogastrone Glycoproteins of about 170 kD that have protein kinase activity and span the plasma membranes of growing cells, including tumours. They are activated by the binding of epidermal growth factor-urogastrone which then initiates DNA and protein synthesis. They are not found on mitotically quiescent cells except in the stomach where they control the synthesis and release of digestive enzymes and gastric acid. Transforming growth factor alpha also binds to and activates these receptors.
(12 Dec 1998)
receptors, fibroblast growth factor Specific molecular sites or structures on cell membranes that react with fibroblast growth factors (both the basic and acidic forms), their analogs, or their antagonists to elicit or to inhibit the specific response of the cell to these factors. These receptors frequently possess tyrosine kinase activity.
(12 Dec 1998)
receptors, growth factor Cell surface receptors that bind growth or trophic factors with high affinity, triggering intracellular responses which influence the growth, differentiation, or survival of cells.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á